ArticleScience progress
Genetically predicted serum uric acid and pulmonary arterial hypertension: Mendelian randomization with an exploratory NHANES risk-burden analysis.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveSerum uric acid (SUA) has been associated with cardiovascular and pulmonary vascular disease, but whether SUA has a causal role in pulmonary arterial hypertension (PAH) remains uncertain. This study aimed to evaluate the genetic association between SUA and PAH using Mendelian randomization (MR), with an exploratory population-based analysis in individuals with a higher PAH-related risk-factor burden.MethodsWe conducted two-sample MR using publicly available genome-wide association study (GWAS) summary statistics. The European-ancestry SUA dataset (GCST90014015) was used as the primary exposure dataset, and a cross-population SUA dataset (GCST90018977) was used as exploratory secondary evidence. PAH outcome data were obtained from the largest available PAH GWAS. Cross-sectional NHANES 2003-2018 data were used only as descriptive exploratory context based on a PAH-related risk-factor burden.ResultsGenetically predicted SUA was associated with higher PAH risk in the European primary analysis (GCST90014015: OR=1.31, 95% CI 1.03-1.68,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.